AUTHORS
Amy Li, MD, PhD, Giulia Trevellin2, Jared Brown, PhD3, Kelly P Burke, MD, PhD4, Jonathan Li5, Marie McConkey, PhD6, Jeong-mi Lee, PhD7, Peter The Sage, PhD8, Arlene Helen Sharpe, MD, PhD9, Benjamin Ebert, MD, PhD10
AFFILIATIONS
1 Dana Farber/ Boston Children’s Blood Disorder and Cancer Center, Boston, Massachusetts, United States
2 Harvard Medical School, Boston, Massachusetts, United States
3 Dana Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana Farber Cancer Institute, Boston, Massachusetts, United States
5 Yale School of Medicine, New Haven, Connecticut, United States
6 Dana Farber Cancer Institute, Boston, Massachusetts, United States
7 Brigham and Women's Hospital, Boston, United States
8 Brigham and Women's Hospital, Boston, United States
9 Harvard Medical School, Boston, Massachusetts, United States
10 Dana Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Thalidomide and its analogs (TA) are “molecular glue” drugs that degrade the lymphoid transcription factors IKZF1 and IKZF3, a mechanism central to their activity in multiple myeloma and their effects on lymphocyte function. Although TA can promote inflammation in cancer, they also show efficacy in chronic graft versus host disease (cGVHD) and other autoimmune disorders, highlighting the need to characterize their context-dependent effects on immune tolerance in immunocompetent mouse models. Because germinal center (GC) dysregulation and autoreactive B cells drive the pathogenesis of cGVHD and other autoimmune diseases, we examined the impact of TA treatment on regulation of GC responses using a transgenic mouse model with a two amino acid substitution in the mouse Crbn gene (Crbn KI: CrbnV380E/I391V) that enables TA-induced degradation of murine Ikzf1 and Ikzf3.
We treated Crbn KI mice with mezigdomide (MEZI) and pomalidomide (POM) and found that TA preferentially expanded regulatory T cells (Treg) in lymphoid and mucosal tissues. TA treatment also increased Treg frequency in Crbn KI mice bearing subcutaneous melanoma tumors. We hypothesized that TA may enhance Treg-mediated suppression of GC responses, underlying their efficacy in cGVHD. To model GC development, we immunized mice with the model antigen NP-OVA (4-hydroxy-3-nitrophenylacetyl conjugated to chicken ovalbumin). In NP-OVA-immunized Crbn KI mice, MEZI treatment induced a sustained increase in Treg and follicular regulatory T cells (Tfr) numbers throughout GC resolution and memory. Even though B cell numbers were largely unchanged, MEZI-treated mice had reduced NP-specific IgG, consistent with enhanced suppression of GC formation and antibody responses.
We next asked whether TA directly promote Treg differentiation or expansion. MEZI and POM impaired the differentiation of naïve CD4+ T cells into Foxp3+ Treg, suggesting they do not enhance induced Treg generation. Instead, Treg isolated from Crbn KI mice and cultured with MEZI or POM survived IL-2 withdrawal. Consistent with the known function of Ikzf1 in suppressing Il2 expression in other T cells, MEZI induced IL-2 production by Treg, and we show that de-repressed IL-2 was necessary and sufficient for Treg survival.
To identify additional MEZI-induced gene expression changes that might support Treg expansion or differentiation, we performed RNA sequencing on Crbn KI Treg cultured with MEZI vs. control, and with or without IL-2. MEZI and IL-2 upregulated overlapping genes, consistent with MEZI-induced IL-2 expression, but MEZI also differentially regulated genes compared to IL-2, reflecting broader effects of Ikzf1 and Ikzf3 degradation. These included genes critical for Tfr differentiation, suggesting that these transcriptional changes support Tfr differentiation in vivo.
Here we show that TA expand Treg in diverse inflammatory settings, including in a model of GC responses. Immunized TA-treated mice exhibit increased proportions and numbers of Treg and Tfr, likely contributing to reduced antigen-specific antibody titers. In vitro, TA directly promote Treg survival by inducing IL-2 production, and TA-driven transcriptional changes support Tfr differentiation. Together, our data suggest that TA enhance immunosuppression in the GC by promoting Treg expansion and differentiation into Tfr, providing a potential mechanistic basis for their efficacy in cGVHD and other autoimmune disorders.
DISCLOSURES
Amy Li, MD, PhD: No relevant conflicts of interest to declare.